hotspot -WSS

hotspot

author：leisure time 2025-09-28 01:36:43 - browse：33

Cambridge: Biogen — Ruby Wallau for STAT

Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a new acquisition.

The Cambridge, Mass., drugmaker announced Wednesday that it will acquire Human Immunology Biosciences, or HI-Bio, for $1.15 billion and up to $650 million in additional payments if certain milestones are met.

HI-Bio, which is based in San Francisco, is developing therapies for immune-mediated diseases like primary membranous nephropathy and IgA nephropathy, both of which impact kidney function. The startup’s lead drug, felzartamab, is a monoclonal antibody that selectively depletes CD38+ and natural killer cells in the hopes of alleviating the disease’s effects. It has already completed Phase 2 studies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： What to do when lifesaving products contribute to climate change

WSS

How to pay for weight loss drugs and save Medicare

Investment in vaccine development is lagging, report finds

Why you shouldn’t ask, “What country has the best health care?”

Syphilis numbers in the United States reach record heights

Takeda, Janssen join wearable maker to measure scratching

FDA investigates CAR

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

New clues to why women have higher risk of autoimmune disorders

ChatGPT in medicine: STAT answers readers' burning questions

What to do when lifesaving products contribute to climate change

Moonlake's readout produced a cash windfall. Risks remain

Organ aging and disease risk measured by new blood test

In age of alternative facts, a scholarly course on calling out crap

J&J to emphasize cancer drugs, stop much of its vaccine research

After affirmative action ruling, medical educators look to 'holistic review'

BIO selects John Crowley as new CEO

leisure time

White House pharmacy plagued with problems, investigation finds

Rep. Raul Ruiz on the physician shortage and more

White House pharmacy plagued with problems, investigation finds

Rep. Raul Ruiz on the physician shortage and more

30 years of 'Listening to Prozac'

Health Care Service Corp to buy Cigna Medicare Advantage plans

leisure time

entertainment

focus

explore